Trial Profile
Efficacy and Toxicity of Blinatumomab in the French Compassionate Use Program (ATU) for Adult Patients With B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Refractory, in Relapse, or With Positive Minimal Residual Disease
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- Acronyms FRENCH-CYTO
- 21 Jun 2020 Status changed from recruiting to completed according to results presented at the 25th Congress of the European Haematology Association.
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 29 Nov 2018 New trial record